Premium
Intracoronary secretin increases cardiac perfusion and function in anaesthetized pigs through pathways involving β‐adrenoceptors and nitric oxide
Author(s) -
Grossini Elena,
Molinari Claudio,
Morsanuto Vera,
Mary David A. S. G,
Vacca Giovanni
Publication year - 2013
Publication title -
experimental physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.925
H-Index - 101
eISSN - 1469-445X
pISSN - 0958-0670
DOI - 10.1113/expphysiol.2012.070607
Subject(s) - secretin , medicine , endocrinology , nitric oxide , perfusion , vasodilation , receptor , chemistry , secretion
New Findings• What is the central question of this study? What is the primary effect of secretin on cardiac function and perfusion? Are the autonomic nervous system, secretin receptors and NO involved? • What is the main finding and its importance? Intracoronary secretin increases cardiac perfusion and function through β‐adrenoceptors and secretin receptors in the anaesthetized pig, with the coronary vasodilatation involving NO release. As downstream effectors of the observed NO production, cAMP/protein kinase A and phosphoinositide 3‐kinase/Akt‐related signalling were found. Thus, secretin could play an important role in the modulation of cardiovascular reflexes elicited by stimulation of gastrointestinal mechano/chemoreceptors. Moreover, secretin could hypothetically have a potential use in the treatment of acute left ventricular failure or ischaemic heart disease.Secretin has been implicated in cardiovascular regulation through its specific receptors, as well as through β‐adrenoceptors and nitric oxide, although data on its direct effect on coronary blood flow and cardiac function have remained scarce. The present study aimed to determine the primary in vivo effect of secretin on cardiac function and perfusion and the mechanisms related to the autonomic nervous system, secretin receptors and NO. In addition, in coronary endothelial cells the intracellular pathways involved in the effects of secretin on NO release were also examined. In 30 pigs, intracoronary secretin infusion at 2.97 pg for each millilitre per minute of coronary blood flow at constant heart rate and aortic blood pressure increased coronary blood flow, maximal rate of change of left ventricular pressure, segmental shortening, cardiac output and coronary NO release ( P < 0.05). These responses were graded in a further five pigs. Moreover, while blockade of muscarinic cholinoreceptors ( n = 5) and of α‐adrenoceptors ( n = 5) did not abolish the observed responses to secretin, blockade of β 1 ‐adrenoceptors ( n = 5) prevented the effects of secretin on cardiac function. In addition, blockade of β 2 ‐adrenoceptors ( n = 5) and NO synthase inhibition ( n = 5) prevented the coronary response and the effect of secretin on NO release. All these effects were abolished by a secretin receptor inhibitor ( n = 5). In coronary endothelial cells, the increased NO production caused by secretin was found to be related to cAMP/protein kinase A signalling activated as downstream effectors of stimulation of secretin receptors and β 2 ‐adrenoceptors. In conclusion , in anaesthetized pigs secretin primarily increased cardiac function and perfusion through the involvement of specific receptors, β‐adrenoceptors and NO release.